Cabaletta Bio, Inc. (CABA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & President | 1.09M | -- | 1961 |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer | 765.12k | -- | 1964 |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science & Technology | 776.56k | -- | 1975 |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | -- | -- | -- |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | -- | -- | -- |
| Mr. Anup Marda M.B.A. | Chief Financial Officer | 548.2k | -- | 1978 |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer | -- | -- | 1972 |
| Dr. Samik Basu M.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. Michael Gerard J.D. | General Counsel & Secretary | -- | -- | 1981 |
| Ms. Heather Harte-Hall M.Sc. | Chief Compliance Officer | -- | -- | -- |
Cabaletta Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 161
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Corporate Governance
Upcoming Events
May 13, 2025 at 12:30 PM UTC - May 19, 2025 at 12:30 PM UTC
Cabaletta Bio, Inc. Earnings Date
Recent Events
March 31, 2025 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing